# MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

> **NCT05090566** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 46 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Elranatamab + Nirogacestat
- **DRUG:** Elranatamab + lenalidomide + dexamethasone

## Key facts

- **NCT ID:** NCT05090566
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-10-27
- **Primary completion:** 2025-02-13
- **Final completion:** 2026-03-11
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** A business decision was made by Pfizer to terminate the study and not proceed with the Phase 2 expansion of this study. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05090566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05090566, "MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05090566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*